Background
Immunophenotypic analysis by multiparameter flow cytometry is a powerful tool in the evaluation of hematolymphoid neoplasia. Flow cytometry characterizes cells to classify disease, guide sequential testing, monitor efficacy of treatment (minimal residual disease) and rule out a reactive process.
At MPLN with a turnaround time of one day, flow cytometry is highly specific and sensitive for the evaluation of leukemia, lymphoma and other hematological abnormalities. Interdisciplinary testing on a single sample is reviewed closely to enhance the flow cytometry data; this includes clinical, morphologic, molecular, and genetic findings.
Resources
Flow Cytometry Information Sheet (DEC2018)
Flow Cytometry Tests
Bronchoalveolar Lavage (CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio)
Flow Cytometry Leukemia / Myeloma / Lymphoma
Leukocyte Adhesion Deficiency (CD11b, CD15, CD18) by FLOW*
Lymphocyte Analysis (T-cell subsets, CD19, CD56) by FLOW*
Paroxysmal Nocturnal Hemoglobinuria (PNH) - High Sensitivity by FLOW
T-cell Subsets (CD3, CD4, CD8, CD4:CD8 ratio) by FLOW*